• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma.

作者信息

Boutros Celine, Rouleau Etienne, Majer Michael, Nikolaev Sergei, Robert Caroline

机构信息

Dermatology Unit, Gustave Roussy Cancer Campus, Villejuif, France; Outpatient Clinic, Department of Medicine, Gustave Roussy Cancer Campus, Villejuif, France.

Department of Medical Biology and Pathology, Gustave Roussy Cancer Campus, Villejuif, France.

出版信息

Eur J Cancer. 2021 Jun;150:130-132. doi: 10.1016/j.ejca.2021.03.022. Epub 2021 Apr 23.

DOI:10.1016/j.ejca.2021.03.022
PMID:33901791
Abstract
摘要

相似文献

1
Combination of targeted therapy and immune checkpoint blocker in a patient with xeroderma pigmentosum presenting an aggressive angiosarcoma and a recurrent non-resectable basal cell carcinoma.靶向治疗与免疫检查点阻断剂联合用于一名患有着色性干皮病且伴有侵袭性血管肉瘤和复发性不可切除基底细胞癌的患者。
Eur J Cancer. 2021 Jun;150:130-132. doi: 10.1016/j.ejca.2021.03.022. Epub 2021 Apr 23.
2
Use of vismodegib for the treatment of multiple basal cell carcinomas in a patient with xeroderma pigmentosum.维莫德吉用于治疗着色性干皮病患者的多发性基底细胞癌。
Pediatr Dermatol. 2018 Nov;35(6):e334-e336. doi: 10.1111/pde.13610. Epub 2018 Sep 3.
3
Vismodegib Therapy for Basal Cell Carcinoma in an 8-Year-Old Chinese Boy with Xeroderma Pigmentosum.维莫德吉治疗一名患有着色性干皮病的8岁中国男孩的基底细胞癌
Pediatr Dermatol. 2017 Mar;34(2):163-165. doi: 10.1111/pde.13080.
4
Single or dual immune checkpoint inhibitor as adjuvant therapy in advanced melanoma.单药或双药免疫检查点抑制剂作为晚期黑色素瘤的辅助治疗
Eur J Cancer. 2021 Apr;147:140-141. doi: 10.1016/j.ejca.2021.01.031. Epub 2021 Mar 1.
5
Compassionate use of vismodegib and adjuvant radiotherapy in the treatment of multiple locally advanced and inoperable basal cell carcinomas and squamous cell carcinomas of the skin.维莫德吉的同情用药及辅助放疗在治疗多发性局部晚期且无法手术切除的皮肤基底细胞癌和鳞状细胞癌中的应用
J Am Acad Dermatol. 2014 Apr;70(4):e88-e89. doi: 10.1016/j.jaad.2013.11.032.
6
Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib.用维莫德吉治疗转移性基底细胞癌后出现鳞状细胞癌表型。
J Am Acad Dermatol. 2013 Jul;69(1):e33-4. doi: 10.1016/j.jaad.2013.01.023.
7
Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.在维莫德吉停药后，局部晚期基底细胞癌多灶性复发中未选择出维莫德吉耐药突变。
J Eur Acad Dermatol Venereol. 2019 Nov;33(11):e422-e424. doi: 10.1111/jdv.15741. Epub 2019 Jul 15.
8
A case illustrating successful eradication of recurrent, aggressive basal cell carcinoma located in a scar with vismodegib.一例使用维莫德吉成功根除位于瘢痕处的复发性侵袭性基底细胞癌的病例。
Dermatol Online J. 2018 Feb 15;24(2):13030/qt92k2f96t.
9
Combination of cabozantinib and immune checkpoint inhibitors in advanced renal cell carcinoma: update from the European Society for Medical Oncology 2020.卡博替尼与免疫检查点抑制剂联合用于晚期肾细胞癌：欧洲医学肿瘤学会2020年更新内容
Future Oncol. 2021 Mar;17(9):991-992. doi: 10.2217/fon-2020-1061. Epub 2021 Feb 3.
10
Update to an open-label clinical trial of vismodegib as neoadjuvant before surgery for high-risk basal cell carcinoma (BCC).维莫德吉作为高危基底细胞癌（BCC）手术前新辅助治疗的开放标签临床试验的更新。
J Am Acad Dermatol. 2016 Jul;75(1):213-5. doi: 10.1016/j.jaad.2016.02.1235.

引用本文的文献

1
Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers.22例患有转移性或不可切除癌症的着色性干皮病患者使用免疫检查点抑制剂的疗效和不良事件的回顾性研究。
Front Oncol. 2023 Oct 25;13:1282823. doi: 10.3389/fonc.2023.1282823. eCollection 2023.
2
The French Cohort of DNA Repair-Deficient Xeroderma Pigmentosum Patients: Risk of Hematological Malignancies.法国DNA修复缺陷型着色性干皮病患者队列：血液系统恶性肿瘤风险
Cancers (Basel). 2023 May 10;15(10):2706. doi: 10.3390/cancers15102706.